These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15350028)

  • 1. Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study.
    Mäkitie AA; Reis PP; Irish J; Zhang T; Chin SF; Chen X; Marriott C; Keller A; Perez-Ordonez B; Kamel-Reid S; Siu LL
    Head Neck; 2004 Sep; 26(9):815-22. PubMed ID: 15350028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
    Lin JC; Wang WY; Liang WM; Chou HY; Jan JS; Jiang RS; Wang JY; Twu CW; Liang KL; Chao J; Shen WC
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1342-8. PubMed ID: 17449194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
    Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
    Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
    Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
    Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
    Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
    Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
    Lin JC; Wang WY; Chen KY; Wei YH; Liang WM; Jan JS; Jiang RS
    N Engl J Med; 2004 Jun; 350(24):2461-70. PubMed ID: 15190138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
    Hong RL; Lin CY; Ting LL; Ko JY; Hsu MM
    Cancer; 2004 Apr; 100(7):1429-37. PubMed ID: 15042677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
    Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
    Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
    Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.
    Lo YM; Chan LY; Lo KW; Leung SF; Zhang J; Chan AT; Lee JC; Hjelm NM; Johnson PJ; Huang DP
    Cancer Res; 1999 Mar; 59(6):1188-91. PubMed ID: 10096545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal carcinoma].
    Zhang Y; Gao HY; Feng HX; Deng L; Huang MY; Hu B; Cheng G; Wu QL; Cui NJ; Shao JY
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):982-6. PubMed ID: 15312530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study.
    Wei WI; Yuen AP; Ng RW; Ho WK; Kwong DL; Sham JS
    Head Neck; 2004 Oct; 26(10):878-83. PubMed ID: 15390201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation between the kinetics of plasma EBV DNA levels and clinical response during treatment in patients with nasopharyngeal carcinoma].
    Peng PJ; Zhao C; Liao H; Wang FQ; Zhang L
    Ai Zheng; 2002 Aug; 21(8):817-22. PubMed ID: 12478884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.
    Lo YM; Chan LY; Chan AT; Leung SF; Lo KW; Zhang J; Lee JC; Hjelm NM; Johnson PJ; Huang DP
    Cancer Res; 1999 Nov; 59(21):5452-5. PubMed ID: 10554016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma.
    Le QT; Jones CD; Yau TK; Shirazi HA; Wong PH; Thomas EN; Patterson BK; Lee AW; Zehnder JL
    Clin Cancer Res; 2005 Aug; 11(16):5700-7. PubMed ID: 16115906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of plasma Epstein-Barr virus DNA load as a prognostic marker for nasopharyngeal carcinoma.
    Tan EL; Looi LM; Sam CK
    Singapore Med J; 2006 Sep; 47(9):803-7. PubMed ID: 16924363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
    J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma.
    Tong JH; Tsang RK; Lo KW; Woo JK; Kwong J; Chan MW; Chang AR; van Hasselt CA; Huang DP; To KF
    Clin Cancer Res; 2002 Aug; 8(8):2612-9. PubMed ID: 12171892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
    Ma BB; King A; Lo YM; Yau YY; Zee B; Hui EP; Leung SF; Mo F; Kam MK; Ahuja A; Kwan WH; Chan AT
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):714-20. PubMed ID: 17011447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.